For decades, FDA inspections have followed a familiar rhythm. An investigator arrives onsite, documents are reviewed, batch records are sampled, deviations are scrutinized, and questions are asked. The outcome generated is that observations are written, and companies respond with strategic remediation plans. That model is not disappearing, but it is evolving.

We are entering an era where FDA inspections are increasingly shaped, guided, and informed by artificial intelligence. Not as a futuristic experiment but as a practical necessity driven by complexity, scale, and risk.

This shift is not optional and offers many advantages going forward. It is structural issues that are driving the change.

 

The key issue driving this is a problem of complexity, since pharmaceutical manufacturing today has little resemblance to the industry of 20 years ago.

We now operate in a world of:

  • Continuous manufacturing
  • Real-time release testing
  • Advanced analytics
  • Globalized supply chains
  • Personalized and small-batch therapies
  • Data streams from MES, LIMS, QMS, ERP, and PAT systems

The reality is that the FDA is overseeing more facilities, more products, and more global supply networks than ever before. Under this level of pressure, human review alone cannot scale to match this complexity. Under such circumstances, AI is becoming essential simply to process and interpret the volume of data generated across the industry. This is a task that perfectly suits technology.

When thousands of deviations, complaints, and process parameters are logged across hundreds of facilities, pattern recognition becomes a machine task that AI can handle before it becomes a human one.

 

Risk-Based Inspection Is Now Data-Based Inspection.

The FDA and other major regulatory agencies have long operated under risk-based inspection models promulgated by ICH Q9.  Facilities are prioritized based on product risk, compliance history, recalls, adverse events, and intelligence. What has changed is the depth of data available to support those decisions. Using AI systems, we can now:

  • Aggregate inspection histories across multiple years
  • Identify recurring deviation themes.
  • Detect subtle shifts in product quality metrics.
  • Cross-reference complaint data with manufacturing trends.
  • Analyze, import alerts and supplier performance signals.

This transforms inspection planning from reactive sampling to predictive targeting. This is significant and enables inspectors to ask the question, “Where is the risk emerging? Not just where has it already failed? That’s quite a transition and is more probing in terms of deficiency establishment.

 

Remote Assessments and the Post-Pandemic Shift

As the COVID-19 pandemic progressed, there was an accelerated structural shift towards virtual inspections out of need to keep the supply chain moving. Travel restrictions forced the FDA as well as companies to expand remote interactive evaluations and record requests. Digital documentation review became routine using secure data rooms and data had to be structured, searchable, and transmitted electronically. In some respects, the genie was let out of the bottle as it became realizable that it was possible to complete inspections to a high level of competency without sacrificing compliance. This was a significant breakthrough and once that infrastructure was built and in place, there was no going back.

What we have seen since is a whole raft of tools emerging that can assist with:

  • Reviewing electronic batch records
  • Flagging out-of-trend results
  • Highlighting CAPAs with delayed effectiveness checks
  • Identifying inconsistent root cause language across deviations

Instead of manually sampling 10 records, systems can screen 10,000 and direct investigators to the highest-risk subset. This saves time, improves accuracy, and raises the relevance of the findings discovered. In other words, sharper, faster, and more focused.

 

AI as a Pattern-Recognition Engine

One of the most powerful capabilities of AI in regulatory oversight is pattern detection across large data sets. This is where AI leaves the human capabilities for doing the same functions in the dust.

Our human agency skills lie with our exceptional contextual judgement capabilities rather than performing more simple computational tasks.

In review, AI is exceptional at:

  • Identifying linguistic similarities across deviation narratives
  • Detecting statistical drift in process parameters
  • Finding recurring supplier names across warning letters
  • Recognizing clusters of data integrity signals

For example, a subtle increase in OOS rates across multiple sites using the same raw material supplier may not trigger immediate alarms at each facility. But aggregated AI-driven surveillance can detect cross-site signals that individual inspectors might never see in isolation. This could be huge both from a compliance point of view as well as preventing waste from a supply chain/operational aspect. Clearly, this changes the level at which regulatory oversight operates, from facility-level review to system-level intelligence. This is a significant shift and one which has a material impact on the success of the plant.

 

Data Integrity Is Now a Machine-Readable Issue

Data integrity issues have moved from being about handwriting, backdating, or missing signatures and are now more often associated with metadata, audit trails, system permissions, and electronic record manipulation. As we see with pattern recognition, this is another area where AI systems are well suited to perform better than previous policies. Key among these is:

  • Review audit trail logs for anomalous edits.
  • Identify timestamp irregularities.
  • Detect batch record modifications clustered before release.
  • Flag repetitive “copy-paste” justifications in investigations.

This is not science fiction; it is an algorithmic anomaly detection mechanism that is increasingly embedded into regulatory technology ecosystems to detect issues. Today inspection science has moved into the world of digital forensics and away from the rather dated clipboard past.

 

Globalization Demands Automation

With the scope of regulatory inspection readiness expanding to facilities globally, the FDA inspects facilities across the United States, Europe, India, China, and beyond. The scale is enormous and is expanding as new countries enter the lucrative market for making pharmaceuticals.

With this new broader responsibility, AI can enable:

  • Cross-border inspection intelligence
  • Shared data pools
  • Faster signal aggregation from international partners
  • Harmonized risk scoring models

This is particularly useful as regulatory collaboration expands among agencies such as the FDA, EMA, and PMDA, where AI becomes the connective tissue that allows shared intelligence to be analyzed coherently. Manual systems could never meet this capability to operate at global speed and intensity.

With the rise in the Internal FDA Modernization Agenda, we see the rise in the idea of Cooperative Intelligence.

The FDA itself has been investing in advanced analytics, data modernization initiatives, and AI-enabled tools. These efforts are not speculative; they are strategic.

Regulatory agencies recognize that:

  • Industry is becoming digital.
  • Manufacturing data is increasingly structured.
  • Electronic submissions are standard.
  • Real-world evidence is expanding.

An analog regulator cannot oversee the digital industry. AI is not replacing investigators. It is augmenting them. And this is where the real transformation lies.

 

Cooperative Intelligence

The most effective regulatory future is not “AI vs human.” It is Cooperative Intelligence where human expertise is amplified by machine insight.

Using such an approach, AI can:

  • Surface patterns
  • Rank risk
  • Identify anomalies.
  • Suggest inspection targets.

And while this is being performed, the human contribution is to:

  • Interpret context.
  • Assess intent.
  • Evaluating culture
  • Exercise judgment
  • Determine enforcement action.

So, what is the impact of all this technological interaction? The inspection of the future is likely to begin long before an investigator arrives onsite. The use of AI-driven risk scoring will shape where they go, what they request, and what they focus on. This will prove to be dramatic in terms of impact. The truth about today’s reality is that companies that assume inspections begin at the front door are already behind! The reality is that the digital inspection world is already here and having an impact.

 

What This Means for Industry

For pharmaceutical manufacturers, this shift demands a transformational cultural mindset change. It is no longer sufficient to “pass an inspection.”, although many still believe that this means they are fully compliant when they do. In the future, companies must assume that:

  • Their data trends are being algorithmically evaluated.
  • Their deviation language is pattern-matched.
  • Their supplier performance is cross-referenced.
  • Their CAPA timelines are digitally benchmarked.

Therefore, preparation must evolve from document readiness to data coherence. What this means in real terms is that trend data must tell a consistent story.

  1. Deviation narratives must be rigorous and precise.
  2. Root cause analysis must be defensible beyond surface correction.
  3. Audit trail governance must be robust.
  4. Quality culture must withstand system-level scrutiny.

Key points to pay attention to will be to ensure that one’s systems do not produce noise, otherwise AI will find it, and the implications could be significant. Conversely, if the good news is that if your system does not produce noise then AI will provide confirmation.

 

The Strategic Opportunity

Rather than viewing this as a threat, this provides a significant opportunity for those organizations to get on board early and make a significant shift in their compliance and operational capabilities. Both generate a measurable benefit to the bottom line and improve the products being made for the consumer.

Companies that leverage AI internally for predictive quality, advanced analytics, and structured investigations will be better aligned with how regulators are evolving. It will also increase internal confidence in how they operate. Future inspections will reward companies that have:

  • Transparent data ecosystems
  • Statistical process control maturity
  • Structured investigation methodologies
  • Real-time monitoring frameworks
  • Leadership that understands both compliance and analytics

Organizations that develop these capabilities proactively should not fear AI-driven oversight, rather they should mirror its output.

 

The Bottom Line/Take Home Message

The facts are that FDA and other inspection agencies are becoming AI-driven because they must. With AI capabilities doubling every 90 days the data volume being generated is too vast. The pharmaceutical industry is becoming increasingly complex, and this is resulting in an increasingly interconnected network globally, which requires ever faster responses. Current risk signals are too late in this new environment, and this requires a shift in operational thinking to meet the challenge.

Artificial intelligence is demonstrating to us that operators and regulators can move from reactive observation to predictive surveillance in order to provide a higher quality approach to product manufacturing. For industry leaders, the question is not whether this transformation will occur, but rather they will board the train for the journey ahead because the train has, in some cases, left the station. Yes, the change is already here and happening.

So, is your organization evolving to meet this challenge at the pace that technology is evolving? In a world of AI-enabled regulatory oversight, quality systems must be more than compliant, they must be intelligent.